

L225P Mutation of ABCC8 Gene: A Case of Transient Neonatal Diabetes Mellitus with Thrombophilic Predisposition and Epilepsy

Francesca Silvestri^{1*}, Giulia Maiella², Raffaella Scrocca¹ and Francesco Costantino¹

¹Department of Pediatrics, Sapienza University of Rome, Italy

²Department of Pediatrics, Bambino Gesù Children's Hospital, Italy

*Corresponding author: Francesca Silvestri, Department of Pediatrics, Ospedale Policlinico Umberto I, Sapienza University of Rome, Viale Regina Elena 324, Roma 00100, Italy, Tel: 393489036980; E-mail: francesca.silvestri89@gmail.com

Rec date: Dec 21, 2015, Acc date: Jan 18, 2016, Pub date: Jan 20, 2016

Copyright: © 2016 Silvestri F, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Neonatal diabetes mellitus (NDM) is defined as a rare disorder of glucose metabolism in the first six months of life, transient (TNDM) or permanent (PNDM). TNDM usually resolves by 18 months, though it might relapse later in life; PNDM requires lifelong therapy with insulin or/and sulfonylurea. Etiology of NDM is monogenic and genetically heterogeneous. TNDM is often caused by an over-expression of paternal genes on chromosome 6 or by mutation in KCNJ11. Either way the release of insulin is reduced. PNDM is mostly associated with two genes, KCNJ11 and ABCC8, which encode, respectively, Kir 6.2 and SUR1, subunits of beta cells K-ATP channel. K-ATP channel is constitutively open, hyperglycemia increases the intracellular ATP levels that cause the closure of K-ATP channel and the depolarization of beta cell causing release of insulin. Inactivating mutations in Kir 6.2 or SUR1, K-ATP channel remains open leading to impaired insulin secretion and neonatal diabetes. Here, we report a case of a three months old baby with diagnosis of NDM and thrombophilic predisposition, referred to emergency pediatric department because of intercurrent ipsilateral clonus to the upper and lower right limbs from a few days, successor seizures during the recovery and incidental finding of hyperglycemia. Child was initially treated with insulin, subsequently was started therapy with glybenclamide for 13 months with progressive decal age. The child was also successfully weaned by treatment with sulfonylureas and epilepsy was well controlled with Phenobarbital.

Keywords: Neonatal diabetes mellitus; ABCC8 mutation; Glybenclamide; Epilepsy

Case Report

A three-months-old baby was referred to emergency pediatric department of Policlinico Umberto I Institute, Rome, because of intercurrent ipsilateral clonus to the upper and lower right limbs, in flexion and internal rotation, slight reduction of the rotation of the head to the right, slight reduction in speed and amplitude of the movements of the upper right limb with closed hand. There was asymmetry of the right emiface, slightly closed eye and reduced motility of mouth.

He was born at 39 gestational weeks after a complicated pregnancy by single umbilical artery and placental senescence diagnosed at 24th week. Birth weight: 2470 g, length: 48 cm and Apgar score: 9 and 10. There was family history for autoimmune diseases and ischemic accidents but none for diabetes and seizures.

On physical examination the infant was awake, well hydrated. Respiratory rate: 34/min, Heart rate 133 bpm, temperature 36.9°C, Blood pressure: 65/45 mmHg.

The first-line findings: Ph: 7.4, HCO₃⁻: 19 mEq/L, pCO₂: 41 mmHg, K⁺: 4.8 mmol/L, BE: 0.6 mmol/L, Na: 135 mmol/L, Cl: 94 mmol/L, Ca: 10.8 mg/dL, Glucose: 413 mg/dL, Lactic acid: 1.9 mmol/L.

Epilepsy was unresponsive to intravenous midazolam (0.1 mg/kg), so he received increasing doses of Phenobarbital and Phenytoin with an effective management of epilepsy.

Hyperglycaemia was initially treated with intravenous saline solution and ultrarapid insulin. After, he received subcutaneous insulin with good glycaemic control.




Figure 1: Small area of restricted diffusion in the white matter areas of the corona radiata on the left front seat, referred to an uncertain hypoxic-ischemic acute suffering of parenchyma in acute phase.

EEG showed partial motor epilepticus status with left occipital starting. Blood culture and lumbar puncture were negative. HbA_{1c}: 117 mmol/mol, Apo B1: 1.28 (0.58-1.13), Triglycerides: 297 mg/dl

(37-278), Total Cholesterol: 239 mg/dl (109-204), LDL: 156 mg/dl (35-125), D dimer: 476 ng/ml.

The stool following breastfeeding was normal, showing no pancreatic exocrine deficiency.

Thrombophilia screening showed the following abnormal results: Protein C: 42 (n. v 70-115), Protein S: 54 (n. v 64-124), Factor II G20210A: heterozygous, MTHFR C677T: heterozygous, INR: 1.01, PTT SEC: 39.19 sec (n.v 26.40-36.80), PTT RATIO: 1.32 (n.v 0.90-1.20).

Brain magnetic resonance imaging (MRI) showed a small area of restricted diffusion in the white matter areas of the corona radiata on the left front seat, referred to an uncertain hypoxic-ischemic acute suffering of parenchyma, disappeared at the following MRI, after six days (Figures 1 and 2).

Molecular biology exam performed on DNA examining KCNJ11 (Kir 6.2), INS and ABCC8 (SUR1) genes. The two exons of the gene INS, exon of the gene KCNJ11 and 39 exons of the ABCC8 gene were amplified by PCR and sequenced by capillary electrophoresis. The sequences are inclusive of intron-exon junctions. It was found the mutation in the heterozygous CTGàGCC in position 674 of the gene ABCC8, with substitution of Leucine 225 in Proline (L225P). This is a de novo mutation.




Figure 2: Subacute phase, after six days.

Parents gave their informed consent prior the switching to Glybenclamide. Was administered glargine insulin 6-4 IU and regular one 0.3-0.4 IU/kg at meals for 17 days. After molecular genetics results we had introduced an oral suspension of insulin secretagogue, Glybenclamide for four weeks:

- 1st week 6 IU Glargine + 0.3 mg/kg/day of Glybenclamide.
- 2nd week 4 IU Glargine + 0.4 mg/kg/day of Glybenclamide.
- 3rd week 3IU Glargine + 0.4 mg/kg/day of Glybenclamide.
- 4th week 2/1 IU Glargine + 0.4 mg/kg/day Glybenclamide.

After 2 months of treatment with Glybenclamide, it was started decal age because of reduced demand from 0.4 mg/kg/day to 0.05 mg/kg/day and after 13 months treatment was ended.

Discussion

The etiology of NDM differs from insulin dependent diabetes mellitus Type 1 (DM1). NDM is monogenic, has not anti-insulin, anti-islet cell and anti-glutamic acid decarboxylase antibodies.

Various syndromes and genetic diseases have been reported in PNDM. Our patient has no signs of any syndromes [1-12].

A subgroup of mutations cause severe clinical profile characterized by delayed development of motor, intellectual and social skills, muscle weakness, epilepsy, facial dimorphisms and Neonatal Diabetes (DEND syndrome) [13-15].

Approximately 20% of cases with mutation in KCNJ11 and ABCC8 have extra pancreatic features, the most severe of which is DEND syndrome. Studies suggest that the severity of the clinical phenotype reflects the extent of the reduction of the channel ATP sensitivity [16].

Thus, patient affected by mutations that produce a larger increase in K-ATP are more likely to develop DEND syndrome [14,15].

Our child did not show any intellectual-cognitive and motor deficits but only a partial motor functional limitation linked to cerebral ischemia, so we have excluded DEND syndrome for differential diagnosis, but we hypothesized that stroke and mutation of the K ATP channels caused seizures in synergy.

We would like to focus our attention on epilepsy crisis, which were the first clinical sign to manifest without diabetic ketoacidosis neither neurological delay but the result of a series of concomitant factors such as hyperglycemia, familial hypercholesterolemia, MTHFR and prothrombin gene mutation predisposing to thrombotic risk.

EEG was performed on the first day and the following days of hospitalization. It showed an epileptic alteration and he was treated with phenobarbital (15 mg/twice a day). There are many K ATP channels in the brain so, if they are mutated could cause an elongation of depolarization time with alterations of the electrical conduction.

Treatment with Glybenclamide improved glycemic control, as pointed out by HbA1c levels (median HbA1c pre-Glybenclamide 12.9% (117 mmol/mol), post-transition HbA1c 6.3% (45 mmol/mol), without increase of hypoglycemic episodes. Interestingly, the patient enhanced his production of insulin, requiring progressively smaller doses of Glybenclamide until he stopped treatment at 19 months of age. HbA1c after 3 months from the end of therapy was 4.7% (28 mmol/mol). Our patient, even if showing a mutation already described in literature as PNDM [17,18] to date, after 12 months from the end of therapy does not require any treatment for diabetes. Considering the excellent glycemic control and HbA1c values, we made diagnosis of TNDM.

As previously described in literature, the mutation of the gene ABCC8 (L225P), is mostly responsible of PNDM. We affirm that this mutation doesn't always decode the same phenotype. Our patient certainly suffered of TNDM because after 13 months he was also weaned off Glybenclamide and is currently under an optimal glycemic control. However, our patient is the first case of TNDM induced by substitution of L225P in ABCC8 gene reported in literature [19-28].

Acknowledgement

The contribution of Prof. Barbetti's laboratory to the identification of the mutation is gratefully acknowledged.

References

1. Aguilar-Bryan L, Bryan J (2008) Neonatal diabetes mellitus. *Endocr Rev* 29: 265-291.
2. De León DD, Stanley CA (2011) Permanent Neonatal Diabetes Mellitus.
3. Iafusco D, Massa O, Pasquino B, Colombo C, Iughetti L, et al. (2012) Minimal incidence of neonatal/infancy onset diabetes in Italy is 1:90,000 live births. *Acta Diabetol* 49: 405-408.
4. Slingerland AS, Shields BM, Flanagan SE, Bruining GJ, Noordam K, et al. (2009) Referral rates for diagnostic testing support an incidence of permanent neonatal diabetes in three European countries of at least 1 in 260,000 live births. *Diabetologia* 52: 1683-1685.
5. Metz C, Cavé H, Bertrand AM, Deffert C, Gueguen-Giroux B, et al. (2002) Neonatal diabetes mellitus: chromosomal analysis in transient and permanent cases. *J Pediatr* 141: 483-489.
6. Gottschalk ME, Schatz DA, Clare-Salzler M, Kaufman DL, Ting GS, et al. (1992) Permanent diabetes without serological evidence of autoimmunity after transient neonatal diabetes. *Diabetes Care* 15: 1273-1276.
7. Rubio-Cabezas O, Klupa T, Malecki MT; CEED3 Consortium (2011) Permanent neonatal diabetes mellitus--the importance of diabetes differential diagnosis in neonates and infants. *Eur J Clin Invest* 41: 323-333.
8. Flechtner I, Vaxillaire M, Cavé H, Scharfmann R, Froguel P, et al. (2008) Neonatal hyperglycaemia and abnormal development of the pancreas. *Best Pract Res Clin Endocrinol Metab* 22: 17-40.
9. Woolley SL, Saranga S (2006) Neonatal diabetes mellitus: A rare but important diagnosis in the critically ill infant. *Eur J Emerg Med* 13: 349-351.
10. Bin-Abbas B, Al-Mulhim A, Al-Ashwal A (2002) Wolcott-Rallison syndrome in two siblings with isolated central hypothyroidism. *Am J Med Genet* 111: 187-190.
11. Myers AK, Perroni L, Costigan C, Reardon W (2006) Clinical and molecular findings in IPEX syndrome. *Arch Dis Child* 91: 63-64.
12. Shield JP (2000) Neonatal diabetes: new insights into aetiology and implications. *Horm Res* 53 Suppl 1: 7-11.
13. Gloyn AL, Pearson ER, Antcliff JF, Proks P, Bruining GJ, et al. (2004) Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. *N Engl J Med* 350: 1838-1849.
14. Proks P, Antcliff JF, Lippiat J, Gloyn AL, Hattersley AT, et al. (2004) Molecular basis of Kir6.2 mutations associated with neonatal diabetes or neonatal diabetes plus neurological features. *Proc Natl Acad Sci U S A* 101: 17539-17544.
15. Proks P, Girard C, Haider S, Gloyn AL, Hattersley AT, et al. (2005) A gating mutation at the internal mouth of the Kir6.2 pore is associated with DEND syndrome. *EMBO Rep* 6: 470-475.
16. Flanagan SE, Patch AM, Mackay DJ, Edghill EL, Gloyn AL, et al. (2007) Mutations in ATP-sensitive K⁺ channel genes cause transient neonatal diabetes and permanent diabetes in childhood or adulthood. *Diabetes* 56: 1930-1937.
17. Ellard S, Flanagan SE, Girard CA, Patch AM, Harries LW, et al. (2007) Permanent neonatal diabetes caused by dominant, recessive, or compound heterozygous SUR1 mutations with opposite functional effects. *Am J Hum Genet* 81: 375-382.
18. Masia R, De Leon DD, MacMullen C, McKnight H, Stanley CA, et al. (2007) A mutation in the TMD0-L0 region of sulfonylurea receptor-1 (L225P) causes permanent neonatal diabetes mellitus (PNDM). *Diabetes* 56: 1357-1362.
19. Murphy R, Ellard S, Hattersley AT (2008) Clinical implications of a molecular genetic classification of monogenic beta-cell diabetes. *Nat Clin Pract Endocrinol Metab* 4: 200-213.
20. Russo L, Iafusco D, Brescianini S, Nocerino V, Bizzarri C, et al. (2011) Permanent diabetes during the first year of life: multiple gene screening in 54 patients. *Diabetologia* 54: 1693-1701.
21. Colombo C, Porzio O, Liu M, Massa O, Vasta M, et al. (2008) Seven mutations in the human insulin gene linked to permanent neonatal/infancy-onset diabetes mellitus. *J Clin Invest* 118: 2148-2156.
22. Babenko AP, Polak M, Cavé H, Busiah K, Czernichow P, et al. (2006) Activating mutations in the ABCC8 gene in neonatal diabetes mellitus. *N Engl J Med* 355: 456-466.
23. Vaxillaire M, Dechaume A, Busiah K, Cave H, Pereira S, et al. (2007) New ABCC8 mutations in relapsing neonatal diabetes and clinical features. *Diabetes* 56: 1737-1741.
24. Codner E, Flanagan SE, Ugarte F, Garcý'a H, Vidal T, et al. (2007) AT: Sulfonylurea treatment in young children with neonatal diabetes: dealing with hyperglycemia, hypoglycemia, and sick days. *Diabetes Care* 30: e28-e29.
25. Fanciullo L, Iovane B, Gkiliati D, Monti G, Sponzilli I, et al. (2012) Sulfonylurea-responsive neonatal diabetes mellitus diagnosed through molecular genetics in two children and in one adult after a long period of insulin treatment. *Acta Biomed* 83: 56-61.
26. Klupa T, Kowalska I, Wyka K, Skupien J, Patch AM, et al. (2009) Mutations in the ABCC8 (SUR1 subunit of the K(ATP) channel) gene are associated with a variable clinical phenotype. *Clin Endocrinol (Oxf)* 71: 358-362.
27. Klee P, Bellanné-Chantelot C, Depret G, Llano JP, Paget C, et al. (2012) A novel ABCC8 mutation illustrates the variability of the diabetes phenotypes associated with a single mutation. *Diabetes Metab* 38: 179-182.
28. Patch AM, Flanagan SE, Boustred C, Hattersley AT, Ellard S (2007) Mutations in the ABCC8 gene encoding the SUR1 subunit of the KATP channel cause transient neonatal diabetes, permanent neonatal diabetes or permanent diabetes diagnosed outside the neonatal period. *Diabetes Obes Metab* 9 Suppl 2: 28-39.